ABSTRACT
Objective Endothelial cells that are close to the alveolar-capillary exchange membranes can be activated by SARS-CoV-2 infection leading to cytokine release and macrophage activation syndrome. This could trigger endothelial dysfunction, pyroptosis, and immunothrombosis, which are the vascular changes commonly referred to as COVID-19 endotheliopathy. Thus, this study aimed to identify tissue biomarkers associated with endothelial activation/dysfunction and the pyroptosis pathway in the lung and myocardial samples of COVID-19 patients and to compare them to pandemic Influenza A virus H1N1 subtype – 2009 and Control cases.
Approach and Results Post-mortem lung (COVID-19 group=6 cases; H1N1 group=10 cases, and Control group=11 cases) and myocardial samples (COVID-19=2 cases and control=1 case) were analyzed using immunohistochemistry and the following monoclonal primary antibodies: anti-CD163, anti-interleukin-6 (IL-6), anti-tumor necrosis factor-alpha (TNF-alpha), anti-intercellular adhesion molecule-1 (ICAM-1), and anti-caspase-1. From the result, IL-6, TNF-alpha, ICAM-1, and caspase-1 showed higher tissue expression in the COVID-19 group than in the H1N1 and control groups.
Conclusion Our results demonstrated the presence of endotheliopathy and suggest the participation of the pyroptosis pathway in both the pulmonary and myocardial samples. These conditions might lead to systemic immunothrombotic events that could impair the efforts of clinical staff to avoid fatal outcomes. One of the goals of health professionals should be to identify the high-risk of immunothrombosis patients early to block endotheliopathy and its consequences.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The presented study was approved by the National Research Ethics Committee (Conselho Nacional de Ética em Pesquisa CONEP), protocol number 3.944.734/2020, and 2.550.445/2018. The authors to confirm that all methods were carried out in accordance with relevant guidelines and regulations. Families permitted the postmortem biopsy of the cases of COVID19 and H1N1pdm09.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The authors confirm that all data referred in the manuscript are available.
Nonstandard abbreviations and acronyms
- TNF-alpha
- tumor necrosis factor-alpha
- IL
- interleukin
- H1N1pdm09
- pandemic Influenza A virus H1N1 subtype disease 2009
- ICAM-1
- intercellular adhesion molecule 1
- DAD
- diffuse alveolar damage
- HPF
- high-power field
- MAS
- macrophage activation syndrome
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- COVID-19
- pandemic coronavirus disease 2019
- NLRP3
- NOD-like receptors protein 3
- NF-kB
- nuclear factor-kappa-B
- SIRS
- systemic inflammatory response syndrome
